Summary
Global
Markets Direct's, 'Juvenile Macular Degeneration (Stargardt Disease) - Pipeline
Review, H2 2016', provides an overview of the Juvenile Macular Degeneration
(Stargardt Disease) pipeline landscape.
The
report provides comprehensive information on the therapeutics under development
for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and
discontinued projects.
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Note*: Certain
sections in the report may be removed or altered based on the availability and
relevance of data.
Scope
-
The report provides a snapshot of the global therapeutic landscape of Juvenile
Macular Degeneration (Stargardt Disease)
-
The report reviews pipeline therapeutics for Juvenile Macular Degeneration
(Stargardt Disease) by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
The report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved Juvenile Macular Degeneration
(Stargardt Disease) therapeutics and enlists all their major and minor projects
-
The report assesses Juvenile Macular Degeneration (Stargardt Disease)
therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline projects
-
The report reviews latest news related to pipeline therapeutics for Juvenile
Macular Degeneration (Stargardt Disease)
Reasons To Buy
-
Gain strategically significant competitor information, analysis, and insights
to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage
-
Identify and understand important and diverse types of therapeutics under
development for Juvenile Macular Degeneration (Stargardt Disease)
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of leading
companies
-
Plan mergers and acquisitions effectively by identifying key players and it's
most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding Juvenile
Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
No comments:
Post a Comment